Current status of macrolide-resistant Mycoplasma pneumoniae infections and research progress on drug resis-tance mechanisms
10.3760/cma.j.cn101070-20240817-00521
- VernacularTitle:耐大环内酯类肺炎支原体感染现状与耐药机制研究进展
- Author:
Li LI
1
;
Ming LIANG
1
;
Hong ZHEN
1
;
Linzhen HUANG
1
Author Information
1. 广西医科大学第二附属医院儿科，南宁 530000
- Publication Type:Journal Article
- Keywords:
Mycoplasma pneumoniae;
Macrolide-resistant Mycoplasma pneumoniae;
Resistance mechanism
- From:
Chinese Journal of Applied Clinical Pediatrics
2025;40(7):557-560
- CountryChina
- Language:Chinese
-
Abstract:
Mycoplasma pneumoniae (MP) is one of the major pathogens of community-acquired pneumonia in children, and macrolide antibiotics are the first choice for treating MP infections.However, since the discovery of macrolide-resistant Mycoplasma pneumoniae (MRMP) by Japanese scholars at the beginning of the 21st century, the detection rate of MRMP strains has been increasing globally, and there have been numerous reports of MP resistance around the world.Studies on the mechanism of drug resistance have been conducted both at home and abroad.Meanwhile, the global infection status shows that there are significant regional differences in the proportion of MRMP infections, especially in the Western Pacific region, including China and Japan, where the proportion of infections is the highest.In order to improve the understanding of the current status of MRMP infections and drug resistance mechanisms, the latest progress in the study of the global infection status and drug resistance mechanisms of MRMP is reviewed, aiming to provide a scientific basis for clinical treatment and a reference for future research directions.
